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ABSTRACT
Objectives: To embed an evidence-based intervention
to manage FEver, hyperglycaemia (Sugar) and
Swallowing (the FeSS protocols) in stroke, previously
demonstrated in the Quality in Acute Stroke Care
(QASC) trial to decrease 90-day death and dependency,
into all stroke services in New South Wales (NSW),
Australia’s most populous state.
Design: Pre-test/post-test prospective study.
Setting: 36 NSW stroke services.
Methods: Our clinical translational initiative, the QASC
Implementation Project (QASCIP), targeted stroke
services to embed 3 nurse-led clinical protocols
(the FeSS protocols) into routine practice. Clinical
champions attended a 1-day multidisciplinary training
workshop and received standardised educational
resources and ongoing support. Using the National
Stroke Foundation audit collection tool and processes,
patient data from retrospective medical record
self-reported audits for 40 consecutive patients with
stroke per site pre-QASCIP (1 July 2012 to 31
December 2012) were compared with prospective
self-reported data from 40 consecutive patients with
stroke per site post-QASCIP (1 November 2013 to 28
February 2014). Inter-rater reliability was substantial
for 10 of 12 variables.
Primary outcome measures: Proportion of patients
receiving care according to the FeSS protocols
pre-QASCIP to post-QASCIP.
Results: All 36 (100%) NSW stroke services
participated, nominating 100 site champions who
attended our educational workshops. The time from
start of intervention to completion of post-QASCIP data
collection was 8 months. All (n=36, 100%) sites
provided medical record audit data for 2144 patients
(n=1062 pre-QASCIP; n=1082 post-QASCIP).
Pre-QASCIP to post-QASCIP, proportions of patients
receiving the 3 targeted clinical behaviours increased
significantly: management of fever ( pre: 69%; post:
78%; p=0.003), hyperglycaemia ( pre: 23%; post: 34%;

Strengths and limitations of this study
▪ Evidence of successful ‘scale-up and spread’ of
a complex, proven intervention across an entire
state within a short 8-month time frame.
▪ An example of large systems transformation
involving multidisciplinary clinicians.
▪ Collaboration between researchers who conducted the original trial, clinicians and quality
improvement experts.
▪ Our tight time frame may not have allowed
enough time for full protocol implementation, as
some barriers (eg, treatment of hyperglycaemia
with insulin) require further attention.
▪ Use of self-reported processes of care audit data.
p=0.0085) and swallowing ( pre: 42%; post: 51%;
p=0.033).
Conclusions: We obtained unprecedented statewide
scale-up and spread to all NSW stroke services of a
nurse-led intervention previously proven to improve
long-term patient outcomes. As clinical leaders search
for strategies to improve quality of care, our initiative is
replicable and feasible in other acute care settings.

BACKGROUND
Implementation science has emerged as a
rigorous ﬁeld of enquiry aiming to generate
better evidence about efforts to embed clinical evidence into routine healthcare practice.1 Since it can take an average of 17 years
for implementation of evidence into standard practice,2 evidence to inform selection of
strategies is sorely needed to accelerate the
pace towards evidence-based practice in a
more predictable manner. The Cochrane
Effective Practice and Organisation of Care
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(EPOC) group has conducted systematic reviews of interventions aiming to improve knowledge translation.1 3 4
Active, targeted implementation strategies have been
shown to be effective in closing evidence-practice gaps
and changing clinician behaviour. However, no single
implementation strategy is effective in all circumstances
for all healthcare settings.1 Further research is required
into effective models of care;5 6 in addition, the context
and barriers to practice change known to inﬂuence the
success of intervention implementation should be
addressed effectively.1
One of the difﬁculties in achieving rapid uptake is
that evidence generated from clinical trials is difﬁcult to
implement more widely, often due to lack of published
details about precisely how the trial was conducted7 and
a lack of process evaluation, in particular for complex
interventions.8 9 ‘Scalability’ of interventions to promote
evidence-based practice in healthcare is worthy of
greater scientiﬁc study. ‘Scalability’ is ‘the ability of a
health intervention shown to be efﬁcacious on a small
scale and or under controlled conditions to be
expanded under real-world conditions to reach a greater
proportion of the eligible population, while retaining
effectiveness’.10 There are relatively few examples in the
published literature where efforts to ‘scale-up and
spread’ beyond elite academic centres have been systematically studied.10 Those that have been published have
focused predominantly on population health initiatives
such as mass immunisation programmes.11 12
Identiﬁcation of these studies from the literature also is
difﬁcult due to the lack of an agreed taxonomy to classify and systematically report them. Furthermore, scalability is often limited by insufﬁcient detail by
researchers of the ‘nuts and bolts’ of a successful
intervention.13
One example of a large-scale intervention involving
scale-up and spread in the acute care setting is the
Michigan Keystone project.14 This cohort study demonstrated improvements in rates of central venous catheter
bloodstream infections in 103 intensive care units
(ICUs) in the USA following introduction of a checklist
of ﬁve evidence-based practices for management of
central venous catheters, implemented using clinical
champions, education and coaching. Simultaneously,
ICUs implemented daily goal sheets to improve communication, an intervention to reduce ventilator-assisted
pneumonia and a programme to improve the safety
culture. Elements of the project subsequently were
adapted and introduced into 200 ICU settings in the UK
in the Matching Michigan study.15 While central venous
catheter bloodstream infections dropped in the UK
ICUs, the Matching Michigan study was not an exact
replica of the original Michigan Keystone project, particularly in terms of implementation of the
intervention.16
As reported elsewhere,17 our team previously developed a successful implementation intervention that
aligned clinical practice in participating stroke units
2

more directly with the evidence. This complex healthcare intervention resulted in signiﬁcant improvements
in patient outcomes. In brief, our Quality in Acute
Stroke Care (QASC) trial showed that a multidisciplinary, nurse-initiated intervention focused on three clinical
protocols to manage FEver, hyperglycaemia (Sugar) and
Swallowing dysfunction (the FeSS protocols; box 1) in
the ﬁrst 72 h of patient admission signiﬁcantly decreased
death and disability by 16% ( p=0.002). These dramatic
improvements in death and dependency were larger
than any pharmacological18 or organisational19 initiatives for acute stroke known at that time. To design that
intervention, we had incorporated best practice from
the ﬁeld of implementation science to design a standardised intervention comprising systematic local barrier
identiﬁcation,20 reinforcement of multidisciplinary teamwork,21 local adaptation22 and use of site champions.23
This cluster randomised controlled trial also showed that
this intervention changed process of care as well as
patient outcomes by signiﬁcantly reducing fever, glucose
levels and improved swallow screening practices.24
Our next challenge as a team of clinicians, academics
and health service managers was how to ‘scale-up and
spread’ this effective intervention beyond original trial
sites to reach all hospitals in New South Wales (NSW),
the most populous Australian jurisdiction. We did not
want to leave the uptake of this intervention to chance.
Instead, we aimed to test our success in scaling up
these three clinical protocols to all 36 NSW stroke
services using those intervention elements demonstrated
to be effective in the QASC trial. Known as the
QASC Implementation Project (QASCIP), this statewide
scale-up of our proven intervention was evaluated
rigorously by measuring impact on clinical care for
fever, hyperglycaemia and swallowing dysfunction

Box 1 Summarised elements of the Fever, Hyperglycaemia
(Sugar) Swallowing (FeSS) clinical protocols used in the
Quality in Acute Stroke Care (QASC) Implementation Project
(QASCIP)
▸ Fever
– Temperature readings 4–6 hourly for the first 72 h
– If temperature>37.5°C, treat with paracetamol
▸ Sugar (hyperglycaemia)
– Formal venous glucose on admission to the emergency
department or stroke service
– Blood sugar readings 4–6 hourly for the first 72 h for
people with known diabetes
– Blood sugar readings 4–6 hourly for the first 48 h for
people not known to have diabetes
– If glucose>10 mmol/L, treat with insulin
▸ Swallowing
– Swallow screen or swallow assessment within 24 h of
admission and prior to being given oral food, drink or
medications
– Referral to speech pathologist for full assessment for
those who fail the swallow screen
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management as described below. We report the ﬁndings
based on the SQUIRE (Standards for Quality
Improvement Reporting Excellence) guidelines.25
METHODS
All NSW stroke services (n=36) were invited to participate in this prospective pre-test/post-test study: these
comprised 31 sites with dedicated stroke units in large
hospitals and ﬁve sites without dedicated stroke units
but with integrated hospital stroke services based on
agreed hospital service delineations.26 Those sites which
had previously participated in the QASC trial were also
eligible to participate (irrespective of whether they had
been allocated to the intervention or control group).
A personal invitation letter and study summary were
sent to senior clinical and management executives in
each stroke service including chief executives of the
respective local health district; clinical directors of all 36
stroke services; directors of nursing; directors of allied
health; stroke clinical nurse consultants/coordinators
and, where applicable, stroke service/stroke unit nurse
unit managers. In our invitation, sites were asked to
consent to nominate up to three clinical stroke champions to act as local change agents for ‘scale-up and
spread’ of the intervention. Our study then faithfully
replicated the intervention from the QASC trial as
described below (box 2).
Scale-up and spread initiative
Clinical champions from each participating hospital
attended a 1-day educational workshop where education
and training were provided about: (1) the FeSS protocols, including ASSIST swallow screening training (see
below); (2) barrier and enabler identiﬁcation; and (3)
reinforcement of multidisciplinary teamwork. A small
change to the Sugar protocol used in the QASC trial was
made whereby the treatment point for raised glucose
was lowered from 11 to 10 mmol/L to align with the
newly released Australian Diabetes Society Guidelines for
Routine Glucose Control in Hospital.27 The ASSIST swallow
screening training package consisted of online

Box 2 Summarised elements of the implementation strategy used in the Quality in Acute Stroke Care (QASC)
Implementation Project (QASCIP)
The QASCIP implementation intervention consisted of:
▸ Informing Local Health District (LHD) chief executives and key
health service managers
▸ Engaging multidisciplinary clinicians and clinical champions at
each participating hospital
▸ A 1-day multidisciplinary training workshop for clinical champions in order to assess barriers and enablers, provide education and reinforce teamwork
▸ Interactive educational meetings and provision of educational
resources
▸ Support in the form of site visits, telephone and email contact
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568

education with case scenarios and a knowledge test to
train non-speech pathologists (ie, nurses and medical
staff ) to competently perform a swallow screen for
patients with acute stroke. Patients who failed the
swallow screen were to be kept nil by mouth and
referred to a speech pathologist for a swallow assessment. Clinical champions were also provided with implementation tools and educational materials including a
prepackaged PowerPoint presentation for use in their
sites; a ‘barrier and enabler’ assessment tool, an implementation plan template, and a suggested implementation and evaluation timeline (all are freely available for
download at http://www.acu.edu.au/qasc). The aim of
this suite of clinical and educational tools was to facilitate efforts by clinical champions at their own sites to
lead implementation in their local stroke services based
on an effective intervention.
Clinical champions were charged with targeting all
clinicians in their stroke services. They were not obliged
to engage their respective emergency department or
ICU but rather to concentrate their efforts on changing
practice in their stroke service. We allowed 1 month for
clinical champions to return to their sites and begin
implementation. Prior to the start of the postimplementation audit and consistent with the QASC trial,17 we
also allowed for an additional 3-month bedding down
period to establish the FeSS clinical protocols into
routine care. All participating sites were visited by the
project coordinator and the NSW Agency for Clinical
Innovation (ACI) Stroke Network Manager at least once
during this ‘bedding down’ period. The project coordinator provided monthly proactive and reactive ongoing
support to the clinical champions via email and
telephone.
Retrospective medical audit pre-QASCIP
To establish pre-QASCIP practice, following consent
from stroke services, the National Stroke Foundation
(NSF) provided the researchers with self-reported data
previously collected independently of our study as part
of the NSF National Clinical Audit (using patient data
for stroke admissions between 1 July 2012 and 31
December 2012)28 and the NSF Organisational Survey
(data collected 1 April to 31 May 2013).29 Using the
established NSF audit web-based tool,30 clinical champions had conducted this retrospective audit of the
records for the ﬁrst 40 consecutive patients with a
primary diagnosis of stroke admitted to the stroke unit
between 1 July 2012 and 31 December 2012, excluding
patients with subarachnoid haemorrhage, subdural and
extradural haematoma, and transient ischaemic attacks.
Any sites which had not participated in either of these
previous NSF audits provided self-reported retrospective
preintervention data directly to the researchers using
the NSF web-based audit tool in an identical manner
and time period.
All clinical champions received training at the
QASCIP workshop on the auditing process. In addition,
3
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online audit training was made available to the site auditors through the NSF website with monthly support
teleconferences.
Instrument
For the preimplementation and postimplementation
audit, we used 19 existing relevant items from the 2013
NSF Clinical Audit as follows: fever: n=4; hyperglycaemia:
n=5; swallowing: n=4 and patient demographics: n=6. As
collected through the NSF National Clinical Audit, these
questions assessed frequency of temperature and glucose
monitoring and treatment for the ﬁrst 72 h after stroke
admission. The swallowing questions examined the time
and date the swallow screen was completed, if patients
were kept nil by mouth before a screen and prior to food,
ﬂuids or oral medications, and if patients were kept nil by
mouth after a failed screen and subsequent referral to a
speech pathologist. In addition, we also accessed eight
existing relevant items from the 2013 NSF Organisation
Survey regarding existing hospital and stroke service
characteristics, namely location (metropolitan/rural);
presence of dedicated stroke unit (yes/no); regular
multidisciplinary team meetings (yes/no); whether there
were existing clinical care pathways for: stroke, fever management, hyperglycaemia management, swallowing management (yes/no for each); and current use of the
ASSIST swallowing screening tool (yes/no).
Prospective medical audits post-QASCIP
Participating sites were also required to conduct a selfreported prospective audit for the ﬁrst 40 consecutive
patients from the postimplementation period, namely 1
November 2013 to 28 February 2014, using identical
NSF tools and equivalent inclusion criteria. The postimplementation audits were started 4 months after the
one-day educational workshop, with a total of 8 months
between this workshop and completion of the postimplementation audits.
Using the postimplementation cohort, inter-rater reliability was undertaken through repeat medical record
audits for four key outcome measures for fever, ﬁve for
hyperglycaemia and three for swallowing dysfunction at
each site using different auditors as per the standard
NSF data collection method to measure data reliability.28
Stroke services were asked to reaudit the ﬁrst ﬁve consecutive patients; however, those stroke services with a
lower volume of patients with stroke (<20 in the postimplementation cohort) were only required to reaudit
records for three patients.
Data analysis
De-identiﬁed data were analysed by an independent statistician. Aboriginality, age group, sex, history of diabetes
and premorbid modiﬁed Rankin Score (mRS) were
compared between patients included in the preimplementation and postimplementation audits using a logistic regression model, and length of stay was compared
between the precohorts and postcohorts using a linear
4

model; these models included pre-post as the explanatory variable and used a generalised estimating equations (GEEs) approach to adjust for correlation of
observations within hospitals.
The number and proportion of patients with each of
the monitoring and treatment elements for all three of
the FeSS protocols were compared between the preimplementation and postimplementation periods. In addition, we calculated overall monitoring adherence,
overall treatment adherence and a composite measure
of appropriate monitoring and treatment for all three of
the FeSS protocols.
To compare monitoring and treatment outcomes from
preimplementation to postimplementation, logistic
regression analyses were undertaken, which included
audit period ( preimplementation or postimplementation) as the primary predictor variable of interest. The
logistic regression models were ﬁt within a GEEs framework to adjust for correlation of patients within hospitals. ORs and 95% CIs are presented for the key
composite outcomes of appropriate monitoring and
treatment for each of the three FeSS protocols.
For each of the preintervention FeSS monitoring and
treatment practices, we also report the corresponding
proportion for the post-QASC trial ﬁndings from the 10
QASC trial intervention sites; however, small sample
sizes in the audit precluded signiﬁcance testing.
We also examined associations between change in
adherence to the three clinical protocols from preimplementation to postimplementation and the following
factors: (1) volume of stroke admissions (<100 vs ≥100
patients with stroke/year); (2) hospitals with a dedicated
stroke unit and hospitals with a stroke service; (3) hospitals
that participated in the original QASC trial and hospitals
that only participated in the QASCIP; (4) hospitals randomised to the original QASC trial intervention group and
hospitals that only participated in the QASCIP; and (5)
hospital location (rural (population<25 000) vs urban
(population≥25 000)). We generated a separate model for
each of the ﬁve factors which included time (preimplementation/postimplementation), the factor of interest
and the interaction between these two variables. The p
values for the interaction term was used to determine
whether the factor was associated with change in protocol
adherence.
Patients admitted for <24 h were excluded from all
analyses as outcomes were assessed in 24 h blocks of
time. In addition, where patients were only admitted for
48 h, observations for days 1 and 2, but not day 3, were
included in the analyses. Patients not known to have diabetes, with no episode of hyperglycaemia (blood glucose
level (BGL)>10 mmol/L) in the ﬁrst 48 h, were
excluded from the monitoring element 4—M4 in the
analysis as per the clinical protocol. Data recorded as
‘not documented’ and ‘unknown’ were assumed to be
negative and included in the relevant denominator.
κ Values with 95% CIs were calculated to determine
the inter-rater reliability.
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568
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Adherence to clinical audit standards
Adherence to 29 of the 30 relevant standards from the
then proposed UK standards for design and conduct of
a national clinical audit or quality improvement study
was also documented.31

RESULTS
Service characteristics
All 36 stroke service sites agreed to participate. All 32
sites who had participated in the routine 2013 NSF
Clinical Audit data consented to the QASCIP researchers having access to their precollected hospital NSF
audit data. The remaining four stroke services provided
data directly to the researchers. In addition, consent was
provided by the majority of participating sites (n=35) to
access data from the routine 2013 NSF Organisational
Survey to provide hospital characteristics data. The one
site that had not participated in the 2013 NSF
Organisational Survey provided hospital characteristics
directly to the project team.
Most hospitals participating in the study had a dedicated stroke unit (n=31, 86%); most were located in the
metropolitan region (n=32, 89%). Those self-reporting
already having existing protocols were as follows: management of fever (n=32, 89%), hyperglycaemia (n=30,
83%), swallowing (n=35, 97%) and having a clinical care
pathway for stroke (n=32, 92%; table 1).
Pre-QASCIP and post-QASCIP audit results
We obtained data for 1062 patients treated in the preintervention period and 1082 patients in the postintervention period (some hospitals did not have 40 stroke
admissions during the audit periods). There were no signiﬁcant differences between patients in the preimplementation and postimplementation cohorts in terms of
aboriginality ( p=0.09), age group ( p=0.15), gender
( p=0.88), diabetes status ( p=0.24) and premorbid mRS
( p=0.89; table 2).
Length of stay data were available for 901 patients in
the preimplementation audit and 857 in the

postimplementation audit. Length of stay was similar for
the preimplementation cohort (median 6.0 days;
minimum 1.0, maximum 76 days) and for the postimplementation cohort (median 5.0 days; minimum 1.0,
maximum 53 days; p from the GEE linear model=0.18).
Signiﬁcantly increased proportions of patients
received care according to the fever protocol from preimplementation to postimplementation ( pre: 69%; post:
78%; p=0.003; OR 1.6, 95% CI 1.2 to 2.2). Speciﬁcally,
signiﬁcantly higher proportions of patients postimplementation were monitored for fever on days 1–3.
However, of the 135 patients with a febrile episode in
the postimplementation cohort, only 64 (47%) received
paracetamol within 1 h, a non-statistically signiﬁcant
increase from preimplementation (38%; table 3).
There were signiﬁcantly increased proportions of
patients who received care according to the hyperglycaemia (sugar) protocol from preimplementation to
postimplementation ( pre: 23%; post: 34%; p=0.0085;
OR 1.8, 95% CI 1.2 to 2.7). Speciﬁcally, signiﬁcantly
increased proportions of patients from preimplementation to postimplementation had their BGL monitored
on days 1–3. However, of the 205 patients in the postimplementation cohort who had a ﬁnger-prick glucose
level >10 mmol/L, only 56 (27%) received insulin within
the 1 h recommended time interval, with no clinical or
statistically signiﬁcant improvement from preimplementation (22%; table 4).
The proportion of patients receiving care according to
the swallowing protocol increased from preimplementation to postimplementation ( pre: 42%; post: 51%;
p=0.033). Speciﬁcally, increased proportions of patients
with acute stroke received a swallow screen or swallow
assessment within 24 h, and prior to receiving oral food
or drink or medications. Similar high proportions of
patients, preimplementation (97%) and postimplementation (95%), who failed a swallow screen subsequently
received a swallow assessment by a speech pathologist as
recommended (table 5).
Of note, statewide overall monitoring and treatment
practices preimplementation were higher when

Table 1 Hospital characteristics
Total hospitals
in study
(n=36)
Hospital location
Metropolitan
Rural
Hospitals with a dedicated stroke unit
Hospitals with a clinical care pathway for managing stroke
Hospitals with regular stroke multidisciplinary team meetings
Hospitals with an agreed management (including assessment and monitoring) protocol for fever
Hospitals with an agreed management (including assessment and monitoring) protocol for hyperglycaemia
Hospitals with an agreed management (including assessment and monitoring) protocol for swallow
Hospitals that use the ASSIST tool

Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568

32 (89%)
4 (11%)
31 (86%)
33 (92%)
34 (94%)
32 (89%)
30 (83%)
35 (97%)
28 (78%)
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Table 2 Patient demographics
Statewide aggregate
Preimplementation
audit
(n=1062)
Aboriginal or Torres Strait Islander
Yes
33 (3.1%)
No
983 (93%)
Refused/Don’t know
46 (4.3%)
Age group
<65
264 (25%)
65 to 74
252 (24%)
75 to 84
350 (33%)
Over 85
193 (18%)
Gender
Male
589 (55%)
Diabetes
Yes
271 (26%)
Premorbid mRS (prior to admission to hospital)
0 or 1 (None or minimal
672 (66%)
disability)

Postimplementation
audit
(n=1082)

p Value

QASC trial
Intervention
hospitals
(n=603)

23 (2.1%)
1034 (96%)
25 (2.3%)

0.09

5 (0.8%)
506 (84%)
92 (15%)

241 (22%)
252 (23%)
350 (33%)
232 (22%)

0.15

197 (33%)
141 (23%)
171 (28%)
94 (16%)

599 (55%)

0.88

358 (60%)

254 (23%)

0.24

108 (18%)

692 (66%)

0.89

476 (93%)

mRS, modified Rankin Score; QASC, Quality in Acute Stroke Care.

compared with data collected from the 10 intervention
hospitals at conclusion of the original QASC trial which
had been completed some 24 months earlier, for
example, monitoring adherence for fever (QASCIP preimplementation: 69% vs QASC trial: 44%); hyperglycaemia (QASCIP preimplementation: 23% vs QASC
trial: 3.5%) and swallowing (QASCIP preimplementation: 42% vs QASC trial: 10%).
There were no signiﬁcant differences in change in
whether patients were monitored and treated according
to the protocol from preimplementation to postimplementation and number of stroke admissions (<100 vs
≥100 patients with stroke/year) for fever ( p=0.75),
hyperglycaemia ( p=0.95) and swallowing ( p=0.28).
Similarly, there were no signiﬁcant differences in preimplementation to postimplementation change in adherence between hospitals with a dedicated stroke unit
compared with hospitals without (ie, with only a stroke
service) for the fever protocol ( p=0.81), the hyperglycaemic protocol ( p=0.31) and the swallowing protocol
( p=0.09).
No signiﬁcant differences were found between rural
and urban hospitals and change in whether patients
were monitored and treated according to fever protocol ( p=0.11) or the swallowing protocol ( p=0.052).
There were, however, statistically signiﬁcant improvements for monitoring and treatment according to the
hyperglycaemic protocol in urban sites ( preimplementation: n=228 (23%); postimplementation; n=356
(35%)) when compared with rural sites ( preimplementation: n=12 (14%); postimplementation; n=7
(11%; p=0.0006)).
There were no signiﬁcant differences between hospitals that participated in the original QASC trial and
6

hospitals that only participated in the QASCIP in
pre-post change in monitoring and treatment adherence
to: the fever protocol ( p=0.48), the hyperglycaemic
protocol ( p=0.85) and the swallowing protocol ( p=0.57).
Likewise, there was no difference between hospitals randomised to the original QASC trial intervention group
and hospitals that only participated in the QASCIP and
change from preimplementation to postimplementation
in whether patients were monitored and treated according to the fever protocol ( p=0.54) or the swallowing
protocol ( p=0.77). However, adherence to the hyperglycaemic protocol in those hospitals which received the
QASC intervention in the original trial remained consistent from preimplementation (37%) to postimplementation (35%), but increased from preimplementation
(16%) to postimplementation (33%) for the hospitals
which did not receive the QASC intervention as part of
the original trial ( p=0.02).
Inter-rater reliability data were provided for a total of
148/1082 (14%) postimplementation patients from all
participating hospitals. For 10 of the 12 patient variables
in the postimplementation clinical audit, the κ values
indicated substantial inter-rater reliability (ie, >0.6;
ﬁgure 1).32
Adherence to audit standards
Of the 30 proposed UK standards for design and
conduct of a national clinical audit or quality improvement study, 29 standards were relevant to our audit. One
standard was not applicable as our audit did not involve
any electronic data linkage. We adhered to 29 of the 29
(100%) proposed standards for the design and conduct
of a national clinical audit or quality improvement study
relevant to our context.
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568
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Table 3 Number and proportion of patients monitored and treated according to fever protocol

Element Monitoring and treatment for fever
M1
M2
M3

T1

Monitoring
Temperature recorded at least four times on day 1
Temperature recorded at least four times on day 2
Temperature recorded at least four times on day 3
Monitoring adherence*
Monitored according to protocol for fever
Treatment
At least one febrile event (temperature≥37.5°C)
Received paracetamol within 1 h of their first febrile event
(temperature≥37.5°C)
Protocol adherence: monitored and treated†
Monitored and treated according to the protocol for fever

Statewide aggregate
Preimplementation Postimplementation
audit
audit
(n=1082)
(n=1062)

OR (95% CI)

924 (87%)
861 (84%)
764 (82%)

1025 (95%)
940 (91%)
833 (88%)

2.68 (1.60 to 4.50) 0.0002
1.89 (1.30 to 2.76) 0.0009
1.56 (1.11 to 2.20) 0.011

545 (93%)
482 (82%)
379 (64%)

802 (76%)

906 (84%)

1.66 (1.18 to 2.34) 0.0033

337 (56%)

149 (14%)
57 (38%)

135 (12%)
64 (47%)

0.89 (0.65 to 1.21) 0.45
1.45 (0.95 to 2.20) 0.08

105 (17%)
19 (18%)

729 (69%)

845 (78%)

1.62 (1.18 to 2.24) 0.0031

258 (44%)

QASC trial
Intervention
group
p Value (n=603)

Day 1 indicates first 24 h since admission to hospital. The protocol recommends that observations should be taken at least six hourly, so there should be at least four separate temperature
recordings during the first 24 h of admission.
Statistically significant p values are shown in bold.
*Must meet all M1, M2 and M3 to be deemed as having been monitored according to protocol.
†Must meet all M1, M2, M3 and T1 to be deemed as having been monitored and treated according to protocol.
QASC, Quality in Acute Stroke Care.
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Element
M1
M2
M3
M4
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568

T1

Monitoring and treatment
Monitoring
Formal VBG measurement in the ED
Finger-prick blood glucose level recorded at least four
times on day 1
Finger-prick blood glucose level recorded at least four
times on day 2
Finger-prick blood glucose level recorded at least four
times on day 3
Monitoring adherence*
Monitored according to the protocol for hyperglycaemia
Treatment
At least one finger-prick glucose level of >10 mmol/L
Insulin received within 1 h of their finger-prick glucose
level of >10 mmol/L
Protocol adherence: monitored and treated†
Monitored and treated according to the protocol for
hyperglycaemia

Statewide aggregate
Preimplementation Postimplementation
audit
audit
(n=1082)
(n=1062)

OR (95% CI)

p Value

QASC trial
Interventio
n group
(n=603)

678 (64%)
533 (50%)

754 (70%)
749 (69%)

1.28 (0.83 to 1.97)
2.50 (1.66 to 3.75)

0.27
<0.0001

184 (31%)
362 (60%)

442 (43%)

679 (66%)

2.81 (1.89 to 4.16)

<0.0001

314 (52%)

179 (60%)

222 (79%)

2.41 (1.54 to 3.78)

0.0001

311 (52%)

301 (28%)

424 (39%)

1.66 (1.11 to 2.48)

0.014

61 (10%)

187 (18%)
41 (22%)

205 (19%)
56 (27%)

1.11 (0.85 to 1.43)
1.32 (0.79 to 2.21)

0.44
0.30

135 (22%)
19 (14%)

240 (23%)

363 (34%)

1.76 (1.16 to 2.69)

0.0085

21 (3.5%)

Day 1 indicates first 24 h since admission to hospital. The protocol recommends that observations should be taken at least six hourly, so there should be at least four separate finger-prick
blood glucose levels taken during the first 24 h of admission to hospital. Formal VBG defined as: blood glucose sample sent to laboratory for analysis.
Statistically significant p values are shown in bold.
*Must meet all M1, M2, M3 and M4 to be deemed as having been monitored according to protocol if the patient is known to have diabetes or is not known to have diabetes but has one or
more episodes of hyperglycaemia (glucose >10 mmol/L). Must meet all M1, M2 and M3 and have no episode of hyperglycaemia (glucose>10 mmol/L) to be deemed as having been
monitored according to protocol if the patient is not known to have diabetes.
†Must meet all M1, M2, M3 and M4 (if applicable, see*) and T1 to be deemed as having been monitored and treated according to protocol.
ED, emergency department; QASC, Quality in Acute Stroke Care; VBG, venous blood glucose.
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Table 4 Number and proportion of patients monitored and treated according to the hyperglycaemia (sugar) protocol

Number and proportion of patients monitored and treated according to swallowing protocol

Element Monitoring and treatment for swallowing

M1
M2
M3

T1
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Table 5

Monitoring
Received a swallow screen within 24 h of admission to hospital
Received a swallow assessment within 24 h of hospital admission
Received a swallow screen or a swallow assessment within 24 h
of hospital admission
Received a swallow screen or a swallow assessment before they
were given food or drink (orally)
Received a swallow screen or a swallow assessment before they
were given oral medications
Monitoring adherence*
Monitored according to protocol for swallow dysfunction
Treatment
Failed the swallow screen
Failed the swallow screen and received a swallowing assessment
by a speech pathologist
Protocol adherence: monitored and treated†
Monitored and treated according to the protocol for swallowing
dysfunction

Statewide aggregate
Preimplementation Postimplementation
audit
audit
(n=1082)
(n=1062)

OR (95% CI)

QASC trial
Intervention
group
p Value (n=603)

453 (43%)
404 (38%)
733 (69%)

562 (52%)
418 (39%)
814 (75%)

1.57 (1.15 to 2.15)
1.01 (0.84 to 1.22)
1.38 (1.09 to 1.74

0.0047
0.91
0.0068

284 (47%)
330 (55%)
491 (81%)

605 (57%)

736 (68%)

1.60 (1.11 to 2.23)

0.013

135 (22%)

550 (52%)

670 (62%)

1.53 (1.10 to 2.13)

0.011

222 (37%)

454 (43%)

565 (52%)

1.50 (1.05 to 2.14)

0.03

65 (11%)

178 (17%)
173 (97%)

230 (21%)
218 (95%)

1.40 (1.05 to 1.86)
0.52 (0.17 to 1.57)

0.02
0.25

95 (16%)
74 (78%)

450 (42%)

556 (51%)

1.47 (1.03 to 2.09)

0.033

62 (10%)

Day 1 indicates first 24 h since admission to hospital.
Statistically significant p values are shown in bold.
*Must meet all M1, M2 and M3 to be deemed as having been monitored according to protocol.
†Must meet all M1, M2, M3 and T1 to be deemed as having been monitored and treated according to protocol.
QASC, Quality in Acute Stroke Care.
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Figure 1 Inter-rater reliability for
12 key individual variables.

DISCUSSION
The reporting of ‘scale-up’ at the national or state level
of an implementation intervention proven effective in
changing clinical practice and improving patient outcomes is limited. There is a pressing need for highquality studies to assess mechanisms by which interventions, shown to be effective in academic centres or hospitals inclined to participate in health services research,
can be ‘scaled up’ to every relevant clinical setting.33
This is one of the few studies to examine a systematic
effort to ‘scale-up and spread’ an effective implementation strategy in acute healthcare. Furthermore, the pace
and geographical scale-up and spread were notable.
Since successful evidence translation can take decades,2
the fact we achieved these signiﬁcant and clinically
important changes within a short 8-month time frame,
only 4 years since publication of our original trial, and
in all stroke services across an entire state, is laudable.
Having tested resources and tools available from the
QASC trial, combined with evidence from the rigorous
process evaluation,24 enabled the rapid replication in
the real world and reduced the evidence-to-practice
translation timeline by many years.
Our implementation study demonstrated signiﬁcant
improvements in adherence to all three FeSS clinical
protocols. Having proven the effectiveness of
10

implementation strategies in the earlier QASC trial provided an incontrovertible foundation for QASCIP itself.
Additional strengths of QASCIP included 100% participation of all NSW stroke services. That this study
embraced smaller stroke services as well as hospitals with
dedicated stroke units was also noteworthy.
The signiﬁcant improvement in monitoring for all
three elements was encouraging, with the exception of
formal venous blood glucose measurement, which warrants further attention. Routine collection of this
measure is potentially achievable through the embedding of serum glucose in electronic pathology orders for
patients with stroke on admission to the emergency
department. However, although treatment practices did
not signiﬁcantly improve for fever (administration of
paracetamol), the number of patients with fever was
small.
Use of insulin for hyperglycaemia remained poor with
less than a third of patients who required insulin not
receiving it. As in the QASC trial, QASCIP did not
supply insulin administration protocols to sites. This was
a deliberate and pragmatic approach as new treatment
protocols of this nature require extensive local consultation and time to implement and it was decided that
hospitals would use their locally agreed current inpatient
protocols while adhering to the principles of best
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568
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practice for glucose management. Anecdotal evidence
gathered at the site support visits highlighted that not all
hospitals had an agreed inpatient insulin administration
protocol for management of hyperglycaemia and that
these sites may have beneﬁted by provision of such
insulin administration guidelines which may then have
improved adherence.
Swallowing surveillance in the form of a swallowing
screen by a non-speech pathologist or a swallowing
assessment by a speech pathologist within 24 h was also
less than optimal even in the postimplementation
cohort (75%). This requires further attention. Patients
continue to be fed and given oral medications prior to a
swallow screen or assessment. In contrast, the percentage
of patients who failed the swallowing screen and correctly received a swallowing assessment by a speech pathologist was encouragingly high preimplementation
(97%), remaining so postimplementation (95%).
Of note, the majority of sites reported already having
fever, hyperglycaemia and swallowing management practices and protocols prior to participation in the study.
Acknowledging that these protocols may have varied
somewhat from the FeSS clinical protocols, higher preimplementation adherence rates might reasonably have
been expected.
Of interest, preimplementation practices for the protocol adherence (ie, monitoring and treatment practices)
for fever, hyperglycaemia and swallowing across the state
were already higher in comparison to postimplementation data collected from the 10 intervention hospitals in
the original QASC trial. This improvement over time was
also reﬂected in national data from the 2013 NSF audit
(fever: monitoring adherence 71%, paracetamol within
an hour 36%; hyperglycaemia: monitoring adherence
18%, insulin treatment 25%; swallowing: monitoring
adherence 39% (no swallowing treatment data available)).34 We speculate that this could potentially be due
to widespread publicity, media reporting and dissemination at conferences and seminars of the results of the
original QASC trial following its publication in the
Lancet in 2011, that is, passive dissemination. The signiﬁcant improvement from pre-to-post for those QASCIP
hospitals which did not receive the intervention as part
of the original QASC trial was potentially due to lower
adherence preimplementation for the non-QASC trial
intervention hospitals.
In view of concerns among policymakers of the intractable differences in health outcomes between rural and
metropolitan populations,35–37 our postaudit data showed
equivalence between rural and urban hospitals in their
adherence to the fever protocol (p=0.11) and was marginally so for the swallowing protocol (p=0.052). This is
encouraging, given the likely limited stafﬁng at rural
speech pathology services, particularly after hours and at
weekends. There were signiﬁcant postimplementation
improvements for monitoring and treatment according to
the hyperglycaemia protocol in urban sites (preimplementation: n=228 (23%); postimplementation: n=356
Middleton S, et al. BMJ Open 2016;6:e011568. doi:10.1136/bmjopen-2016-011568

(35%)) when compared with rural sites (preimplementation: n=12 (14%); postimplementation: n=7 (11%;
p=0.0006)), but further exploration of this difference was
beyond the scope of our study. However, hyperglycaemia
management was poorly attended in all sites regardless of
location.
Our study had several limitations. First, we only had
the resources to evaluate processes of care and not
patient 90-day outcomes as in the original QASC trial.
However, the QASC trial provided robust evidence that
improvements to processes of care, even minimal ones,
can dramatically result in better patient outcomes.
Second, audit data were self-reported, possibly introducing selection bias as well as responder bias. However,
the potential for these biases was present throughout
the study and, having been obtained from a national
clinical audit initiative, unlikely to be unique to our
study alone. Furthermore, any biases would be expected
to be consistent for the preintervention and postintervention cohorts and our primary outcome was improvement over time, rather than absolute values, further
boosted by high inter-rater reliability. Despite these
shortcomings, we successfully adhered to all the relevant
proposed standards for the design, and conduct of a
national clinical audit or quality improvement study31
invites greater conﬁdence. Adherence to rigorous standards for quality improvement studies likely to inform
clinical practice change is essential.38 To the best of our
knowledge, this was the ﬁrst systematic application of UK
Audit Standards in a study of this type internationally.
Reporting on the quality of audit should be imperative
in all large-scale audits.
Collaboration with the NSF was essential for the timely
completion of the study. Use of established data collection tools and existing training methods signiﬁcantly
reduced the cost and timeline for the study. Importantly,
in future, hospitals will be able to reaudit the same processes of care easily and efﬁciently in the future to
measure self-sustainability of improvements made.
Sustainability of practice change is the next frontier in
quality improvement.39 We have also provided valuable
benchmarking data for other Australian states. The
value of using existing data sources (ie, registries and
routinely collected audit data) to measure change over
time cannot be underestimated. Data linkage projects
and the creation of funded, mandated national data sets
with uniform and agreed data deﬁnitions are the way
forward for multisite large-scale statewide or national
quality improvement activities such as this.
We connected researchers with clinicians to develop a
pragmatic, replicable intervention.13 The key to our
success and what makes this implementation study so
unique from other studies16 was the commitment from
the collaborators only to use the proven implementation
strategy from the QASC trial, resisting adopting the
‘kitchen sink’ approach, criticised elsewhere for often
including untested implementation strategies.1 Involving
the researchers who undertook the seminal trial was key
11
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to ensuring that this approach was maintained.
Researchers are rarely involved in evaluation of scale-up,
possibly due to the difﬁculty in securing dedicated
funding for implementation and the need to deliver on
other traditional academic key performance indicators
such as publications and grant income.13 Should research
impact become a metric for researcher performance,
implementation research will ﬂourish as an academic
ﬁeld and clinical translational initiatives such as QASCIP
will increase in number and focus. Despite this, there is a
role for researchers in the scale-up of interventions,13
and particular consideration could be given speciﬁcally
to involving those who conducted the original research
in order to promote implementation ﬁdelity and provide
advice. Dedicated funding for implementation is seriously overdue in Australia and other countries.13 40
CONCLUSION
Our study is one of the few to successfully and systematically replicate methods from a positive implementation
trial. We show, for the ﬁrst time, signiﬁcant statewide
improvements in clinical management of fever, hyperglycaemia and swallowing for patients with stroke through
our clinical translational initiative conducted within a
short 8-month time frame. There was, however, room for
improvement in the proportion of patients receiving
care according to these protocols. Protocol uptake may
have been improved with a longer duration between
implementation and postintervention audit. Barriers to
the hyperglycaemia protocol, in particular, warrant
future attention. Our results clearly demonstrate the
beneﬁts to patients of funding ‘scale-up’ of a proven
implementation strategy across an entire statewide
health system. Nonetheless, further research is recommended to illuminate the complexity of clinical evidence translation on a large scale and at pace.
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